The agreement with the FDA for a clinical trial protocol is a critical regulatory milestone that could lead to full approval of Canalevia-CA1. Given its status as the only treatment for chemotherapy-induced diarrhea in dogs currently approved (even conditionally) by the FDA, this development could significantly enhance Jaguar Health's market position and investor confidence, likely leading to a positive short-term impact on JAGX's stock price.